CIK: 0001856083
Total reported value
$6.1B
Reporting period: 2026-03-31 · Number of holdings: 63
Deep Track Capital, LP disclosed 63 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $6.1B and a quarterly turnover rate of 40.0%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "D"
Deep Track Capital, LP's disclosed holdings carry a Herfindahl concentration index of 0.062 — mathematically equivalent to about 16 equally-sized positions, well below its 63 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 1.72), with a handful of outsized bets alongside many smaller positions.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 18% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim CYTK
-58.8% -$121.5M
Trim GPCR
+4.1% -$79.7M
Trim MAZE
-18.1% -$72.1M
Trim BMRN
-50.0% -$71.7M
Add 260
+57.9% $75.4M
Add ALKS
+79.5% $71.0M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 20.86% | -0.88% | — | |
| 2 | GH | Guardant Health INC | Stock-Healthcare | 5.04% | -0.06% | +19.22% | |
| 3 | IMVT | Immunovant INC | Stock-Other | 4.68% | — | — | |
| 4 | TARS | Tarsus Pharmaceuticals INC | Stock-Other | 4.12% | — | +19.84% | |
| 5 | PCVX | Vaxcyte INC | Stock-Other | 4.08% | +0.79% | +7.50% | |
| 6 | GPCR | Structure Therapeutics INC | Stock-Other | 3.37% | -1.73% | +4.09% | |
| 7 | AXSM | Axsome Therapeutics INC | Stock-Healthcare | 3.04% | -0.70% | -4.35% | |
| 8 | APLSUSD | Apellis Pharmaceuticals INC | Stock-Other | 2.98% | -0.49% | -41.52% | |
| 9 | OCUL | Ocular Therapeutix INC | Stock-Other | 2.72% | +0.97% | +143.93% | |
| 10 | VERA | Vera Therapeutics INC | Stock-Other | 2.70% | +0.15% | +45.55% | |
| 11 | ALMS | Alumis INC | Stock-Other | 2.44% | +2.44% | NEW | |
| 12 | IONS | Ionis Pharmaceuticals INC | Stock-Healthcare | 2.39% | -0.01% | +14.71% | |
| 13 | NUVL | Nuvalent Inc-a | Stock-Other | 2.30% | +2.30% | NEW | |
| 14 | ALKS | Alkermes plc | Stock-Healthcare | 2.07% | +1.07% | +79.52% | |
| 15 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.05% | +1.16% | +57.90% | |
| 16 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.95% | +0.87% | +39.02% | |
| 17 | MAZE | Maze Therapeutics INC | Stock-Other | 1.70% | -1.44% | -18.11% | |
| 18 | ORKA | Oruka Therapeutics INC | Stock-Other | 1.63% | +0.46% | -5.89% | |
| 19 | NRIX | Nurix Therapeutics INC | Stock-Other | 1.61% | -0.77% | -9.82% | |
| 20 | GMAB | Genmab A/s -sp Adr | Stock-Other | 1.61% | +1.60% | NEW | |
| 21 | CYTK | Cytokinetics INC | Stock-Healthcare | 1.48% | -2.30% | -58.82% | |
| 22 | GRAL | Grail INC | Stock-Healthcare | 1.45% | — | +68.44% | |
| 23 | LBRX | Lb Pharmaceuticals INC | Stock-Other | 1.35% | — | — | |
| 24 | MBX | Mbx Biosciences INC | Stock-Other | 1.34% | -0.49% | -15.15% | |
| 25 | BCAX | Bicara Therapeutics INC | Stock-Other | 1.32% | +0.54% | +55.41% | |
| 26 | CMPS | Compass Pathways PLC | Stock-Other | 1.10% | +0.20% | +65.82% | |
| 27 | BMRN | Biomarin Pharmaceutical INC | Stock-Healthcare | 1.06% | -1.38% | -50.00% | |
| 28 | BBIO | Bridgebio Pharma INC | Stock-Healthcare | 1.02% | — | +3.86% | |
| 29 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.95% | -0.29% | -3.60% | |
| 30 | TNGX | Tango Therapeutics INC | Stock-Other | 0.94% | +0.55% | +12.04% | |
| 31 | DFTX | Definium Therapeutics INC | Stock-Other | 0.93% | +0.93% | NEW | |
| 32 | 430 | Terns Pharmaceuticals INC | Stock-Other | 0.92% | +0.37% | +39.64% | |
| 33 | GERN | Geron CORP | Stock-Other | 0.77% | — | -2.43% | |
| 34 | ANIP | Ani Pharmaceuticals INC | Stock-Other | 0.75% | — | +25.61% | |
| 35 | CRMD | Cormedix INC | Stock-Other | 0.70% | -0.39% | +18.96% | |
| 36 | ATAI | Ataibeckley INC | Stock-Other | 0.69% | +0.69% | NEW | |
| 37 | CLDX | Celldex Therapeutics INC | Stock-Other | 0.67% | -0.25% | -32.45% | |
| 38 | COGT | Cogent Biosciences INC | Stock-Other | 0.63% | +0.34% | +120.70% | |
| 39 | CRVS | Corvus Pharmaceuticals INC | Stock-Other | 0.60% | +0.60% | NEW | |
| 40 | DYN | Dyne Therapeutics INC | Stock-Other | 0.59% | -0.33% | -24.53% | |
| 41 | SLNOEUR | Soleno Therapeutics INC | Stock-Other | 0.59% | -0.24% | +7.87% | |
| 42 | ACRS | Aclaris Therapeutics INC | Stock-Other | 0.57% | +0.57% | NEW | |
| 43 | MANE | Veradermics INC | Stock-Other | 0.52% | +0.52% | NEW | |
| 44 | VSTM | Verastem INC | Stock-Other | 0.50% | -0.29% | — | |
| 45 | ✓ | Engene Holdings INC | Stock-Other | 0.49% | — | — | |
| 46 | VRDN | Viridian Therapeutics INC | Stock-Other | 0.45% | -0.95% | -44.79% | |
| 47 | XFOR | X4 Pharmaceuticals INC | Stock-Other | 0.43% | — | +26.45% | |
| 48 | SLDB | Solid Biosciences INC | Stock-Other | 0.42% | +0.42% | NEW | |
| 49 | ENTA | Enanta Pharmaceuticals INC | Stock-Other | 0.40% | — | — | |
| 50 | APGE | Apogee Therapeutics INC | Stock-Other | 0.39% | +0.39% | NEW |
Performance for Q3 2026
+23%
Performance Last 4 Quarters
+100.3%
Based on 79% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 63 | $6.1B | 40 | |
| 2025-12-31 | 55 | $5.6B | 87 | |
| 2025-09-30 | 56 | $3.6B | 70 | |
| 2025-06-30 | 66 | $3.1B | 0 | |
| 2025-03-31 | 69 | $3.1B | 0 | |
| 2024-12-31 | 63 | $2.7B | 0 | |
| 2024-09-30 | 71 | $3.2B | 0 | |
| 2024-06-30 | 68 | $3.4B | 0 | |
| 2024-03-31 | 66 | $3.5B | 0 | |
| 2023-12-31 | 60 | $3.0B | 0 | |
| 2023-09-30 | 63 | $2.6B | 0 | |
| 2023-06-30 | 55 | $2.2B | 0 | |
| 2023-03-31 | 58 | $2.4B | 0 | |
| 2022-12-31 | 60 | $2.4B | 0 | |
| 2022-09-30 | 65 | $2.2B | 0 | |
| 2022-06-30 | 51 | $1.5B | 0 | |
| 2022-03-31 | 52 | $1.6B | 0 | |
| 2021-12-31 | 55 | $1.4B | 0 |
Deep Track Capital, LP's most significant position changes for 2026-03-31: Sold out: Dynavax Technologies CORP (DVAX); New buy: Alumis INC (ALMS); New buy: Nuvalent Inc-a (NUVL); New buy: Genmab A/s -sp Adr (GMAB); New buy: Definium Therapeutics INC (DFTX).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | 260 | Centessa Pharmaceuticals-adr | +1.2% | +57.90% | Add |
| 2 | ALKS | Alkermes plc | +1.1% | +79.52% | Add |
| 3 | OCUL | Ocular Therapeutix INC | +1% | +143.93% | Add |
| 4 | MLTX | Moonlake Immunotherapeutics | +0.9% | +39.02% | Add |
| 5 | PCVX | Vaxcyte INC | +0.8% | +7.50% | Add |
| 6 | TNGX | Tango Therapeutics INC | +0.6% | +12.04% | Add |
| 7 | BCAX | Bicara Therapeutics INC | +0.5% | +55.41% | Add |
| 8 | ORKA | Oruka Therapeutics INC | +0.5% | -5.89% | Trim |
| 9 | 430 | Terns Pharmaceuticals INC | +0.4% | +39.64% | Add |
| 10 | COGT | Cogent Biosciences INC | +0.3% | +120.70% | Add |
| 11 | JANX | Janux Therapeutics INC | +0.3% | +1225.26% | Add |
| 12 | CMPS | Compass Pathways PLC | +0.2% | +65.82% | Add |
| 13 | VERA | Vera Therapeutics INC | +0.2% | +45.55% | Add |
| 14 | IONS | Ionis Pharmaceuticals INC | 0% | +14.71% | Add |
| 15 | GH | Guardant Health INC | -0.1% | +19.22% | Add |
| 16 | SLNOEUR | Soleno Therapeutics INC | -0.2% | +7.87% | Add |
| 17 | CLDX | Celldex Therapeutics INC | -0.3% | -32.45% | Trim |
| 18 | VSTM | Verastem INC | -0.3% | — | Unchanged |
| 19 | IMCR | Immunocore Holdings Plc-adr | -0.3% | -3.60% | Trim |
| 20 | DYN | Dyne Therapeutics INC | -0.3% | -24.53% | Trim |
| 21 | CRMD | Cormedix INC | -0.4% | +18.96% | Add |
| 22 | MBX | Mbx Biosciences INC | -0.5% | -15.15% | Trim |
| 23 | APLSUSD | Apellis Pharmaceuticals INC | -0.5% | -41.52% | Trim |
| 24 | AXSM | Axsome Therapeutics INC | -0.7% | -4.35% | Trim |
| 25 | NRIX | Nurix Therapeutics INC | -0.8% | -9.82% | Trim |
| 26 | XBI | Ss Spdr S&p Biotech ETF | -0.9% | — | Unchanged |
| 27 | VRDN | Viridian Therapeutics INC | -1% | -44.79% | Trim |
| 28 | BMRN | Biomarin Pharmaceutical INC | -1.4% | -50.00% | Trim |
| 29 | MAZE | Maze Therapeutics INC | -1.4% | -18.11% | Trim |
| 30 | GPCR | Structure Therapeutics INC | -1.7% | +4.09% | Add |
| 31 | CYTK | Cytokinetics INC | -2.3% | -58.82% | Trim |
| 32 | DVAX | Dynavax Technologies CORP | — | EXIT | Sold out |
| 33 | ALMS | Alumis INC | — | NEW | New buy |
| 34 | NUVL | Nuvalent Inc-a | — | NEW | New buy |
| 35 | GMAB | Genmab A/s -sp Adr | — | NEW | New buy |
| 36 | DFTX | Definium Therapeutics INC | — | NEW | New buy |
| 37 | ATAI | Ataibeckley INC | — | NEW | New buy |
| 38 | CRVS | Corvus Pharmaceuticals INC | — | NEW | New buy |
| 39 | ACRS | Aclaris Therapeutics INC | — | NEW | New buy |
| 40 | MANE | Veradermics INC | — | NEW | New buy |
| 41 | SLDB | Solid Biosciences INC | — | NEW | New buy |
| 42 | APGE | Apogee Therapeutics INC | — | NEW | New buy |
| 43 | BRD1EUR | Mind Medicine Mindmed INC | — | EXIT | Sold out |
| 44 | KURA | Kura Oncology INC | — | NEW | New buy |
| 45 | IPSC | Century Therapeutics INC | — | NEW | New buy |
| 46 | BEAM | Beam Therapeutics INC | — | NEW | New buy |
| 47 | ATAI | AtaiBeckley Inc. | — | EXIT | Sold out |
| 48 | PSNL | Personalis INC | — | NEW | New buy |
| 49 | XENE | Xenon Pharmaceuticals INC | — | EXIT | Sold out |
| 50 | PMN | Promis Neurosciences INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-13 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-09-06 | Amendment | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-12 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0000354497
Total reported value
$6.1B
512 stks
2023-06-30
Stale — no recent filing
AUM within 0.0% of this institution
CIK 0001800798
Total reported value
$6.1B
3,368 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001733173
Total reported value
$6.1B
332 stks
2026-03-31
AUM within 0.2% of this institution
Institutions with overlapping top holdings
CIK 0001842545
Total reported value
$571.8M
28 stks
2026-03-31
2 of the top 5 holdings overlap, including Ss Spdr S&p Biotech ETF
CIK 0000096223
Total reported value
$14.6B
1,692 stks
2026-03-31
1 of the top 5 holdings overlap, including Ss Spdr S&p Biotech ETF
CIK 0000860645
Total reported value
$83.5M
21 stks
2026-03-31
1 of the top 5 holdings overlap, including Ss Spdr S&p Biotech ETF